SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

. Name and Address of Reporting Person * <u>Randall Kenneth Edward</u>		2. Issuer Name and Ticker or Trading Symbol <u>TC BioPharm (Holdings) plc</u> [TCBP]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner					
(Last) (First) (Middle)	- 3. Date 11/30/2	of Earliest Transact 2022	ion (Mon	th/Day	/Year)			Officer (give title below)		Other (specify below)			
RENAISSANCE CAPITAL PARTNERS LTD 42 SHAD THAMES	4. If Am	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
Street)								Form filed by Mo	re than One I	Reporting Person			
LONDON, X0 SE1 2YD X0													
(City) (State) (Zip)													
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
1. Title of Security (Instr. 3) 2. Trans Date (Month		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownershi Form: Direc or Indirect (I (Instr. 4)	t (D) Indirect			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Series A Warrants	\$5	11/30/2022		Р		70,000		11/30/2022	05/30/2028	Ordinary Shares	70,000	\$0 ⁽¹⁾	70,000	I	By Renaissance Capital Partners Ltd
Series B Warrants	\$5	11/30/2022		Р		70,000		11/30/2022	05/30/2025	Ordinary Shares	70,000	\$0 ⁽²⁾	70,000	I	By Renaissance Capital Partners Ltd
Warrants	\$4.25							04/11/2022	02/10/2028	Ordinary Shares	106,129		106,129	I	By Renaissance Capital Partners Ltd

Explanation of Responses:

1. Series A Warrants were issued as part of a unit comprised of one Ordinary Share, one Series A Warrant, and one Series B Warrant, with a purchase price per unit of %5.00.

2. Series B Warrants were issued as part of a unit comprised of one Ordinary Share, one Series A Warrant, and one Series B Warrant, with a purchase price per unit of %5.00.

<u>/s/ Thomas Nicholls</u> ** Signature of Reporting Person 01/11/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.